PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 09/753,350 Filing Date TRANSMITTAL December 29, 2000 First Named Inventor **FORM** Stephen M. COUTTS Art Unit 1644 (to be used for all correspondence after initial filing) Examiner Name P. Huynh 14 + 93 Attorney Docket Number Total Number of Pages in This Submission 252312005706 refs. **ENCLOSURES** (Check all that apply) After Allowance Communication Drawing(s) Fee Transmittal Form to Group Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): 1. Form PTO-1449 (5 pages with **Express Abandonment Request** Request for Refund 2. Ninety-three (93) References Information Disclosure Statement (3 CD, Number of CD(s) 3. Return Receipt Postcard pages) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm MORRISON & FOERSTER LLP (Customer No. 25226) Shannon Thomas - 52,285 Individual name Signature

I hereby certify that this correspondence is being deporan envelope addressed to: Commissioner for Patents		
Dated: 2-5-04 Signature:	Hav en	(Kari A. Cruz)

Date

February 5, 2004



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA_f 22313-1450, on February 5, 2004.

Kari A. Cruz

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Stephen M. COUTTS et al.

Serial No.: 09/753,350

Filing Date: December 29, 2000

For: CONJUGATES OF T CELL EPITOPE

DEFICIENT IMMUNOGEN ANALOGS

FOR HUMORAL ANERGY AND CHEMICALLY DEFINED NON-

POLYMERIC VALENCY PLATFORM

MOLECULES (AS AMENDED)

Examiner: P. Huynh

Group Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	This Su	applemental Information Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	re the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
	1.97(e)(1) has been provided.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required. However
	if app	licable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing <u>252312005706</u>. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 5, 2004

Respectfully submitted,

By:

Shannon Thomas

Registration No. 52,285

Morrison & Foerster LLP

755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5744 Facsimile: (650) 494-0792

FEB 1 3 2004 B FORM PTO-1449

ATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 252312005706	Application Number 09/753,350				
Applicant		_			
Stephen M.	COUTTS et al.				
Filing Date December 29, 2000 Group Art Unit 1644					
Mailing Date February 5, 2004					

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/12/2001	2001/0007765	Harris et al.			
	2.	08/08/2002	2002/0107389	Coutts et al.		,	
	3.	01/23/2003	2003/0018190	Jones			
	4.	08/28/2003	2003/0162953	Coutts et al.			
	5.	05/17/1977	4,024,222	Ts'o et al.			
	6.	01/13/1981	4,245,110	Engelhard et al.			<u> </u>
	7.	09/15/1981	4289,872	Denkewalter et al.		,	····
	8.	09/14/1982	4,349,538	Levy			
	9.	11/15/1983	4,415,590	Gerzon			
	10.	06/02/1987	4,670,558	Ebel et al.			
	11.	09/05/1989	4,863,713	Goodwin et al.			
	12.	05/08/1990	4,923,985	Gansow et al.			
	13.	01/22/1991	4,987,130	Tsushima et al.			
-	14.	02/09/1993	5,185,433	Dean et al.			
	15.	11/23/1993	5,264,209	Mikayama et al.			
	16.	12/28/1993	5,274,123	Deruelle et al.			
	17.	01/11/1994	5,278,051	Seeman et al.			
	18.	03/29/1994	5,298,403	Danielson et al.			
	19.	01/31/1995	5,386,020	Seeman et al.			
	20.	06/18/1996	5,527,524	Tomalia et al.			
	21.	09/02/1997	5,663,395	Göbel et al.			
	22.	09/30/1997	5,672,662	Harris et al.			
	23.	10/07/1997	5,674,911	Emanuele et al.			
	24.	11/25/1997	5,691,387	Emanuele et al.			
	25.	12/16/1997	5,698,664	Allcock et al.			
	26.	05/05/1998	5,747,244	Sheridan et al.			

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 252312005706 Application Number 09/753,350				350			
IN AN APPLICATION (Use several sheets if necessary)			Applicant Stephen M. COUTTS et al.						
			Filing Date December	29, 2000	Group Art Uni	it 1644			
			Mailing Date February	y 5, 2004					
CA TRADE!	3								
RADE	27.	12/01/1998	5,844,056	Ken	nedy et al.				
	28.	08/03/1999	5,932,462	Har	ris et al.				
	29.	11/23/1999	5,990,237	Ben	tley et al.				
	30.	01/23/2001	6,177,414	Ton	nalia et al.				
	31.	04/09/2002	6,368,612	Lan	za et al.				
			FOREIGN	PATI	ENT DOCUMEN	NTS			
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Transla YES	ation NO
	32.	10/09/1975	DE 2 412 217	Gen	many				X
	33.	08/17/1988	EP 0 278 621	Euro	ope				
	34.	07/29/1992	EP 0 496 074	Euro	ope				
	35.	10/28/1992	EP 0 510 356	Euro	ope				
	36.	02/07/1991	JP 3-500530	Japa	ın			Abstract	
	37.	01/11/1991	JP 3-5495	Japa	ın			Abstract	
	38.	08/07/1992	JP 4-218000	Japa	n			Abstract	
	39.	07/13/1993	JP 5-172814	Japa	ın	1		Abstract	
	40.	07/22/1993	JP 5-504761	Japa	n			Abstract	
	41.	08/19/1993	JP 5-505520	Japa	n			Abstract	
	42.	12/17/1987	JP 62-503171	Japa	n			Abstract	
	43.	01/11/1988	JP 63-005033	Japa	n			Abstract	
	44.	04/02/1998	PT 96503	Port	ugal			Abstract	
	45.	01/10/1991	WO 91/00293	WIP	Ю				
	46.	06/27/1991	WO 91/08753	WIP	PO ,				
	47.	01/23/1992	WO 92/00975	WIP	O			Abstract	
	48.	04/16/1992	WO 92/05897	WIP	О				
	49.	08/20/1992	WO 92/13558	WIP	O				
	50.	12/21/1995	WO 95/34326	WIP	0				
	51.	07/18/1996	WO 96/21469	WIP	0				
	52.	06/17/1999	WO 99/29336	WIP	О				
EXAMIN		al if citation cons	idered, whether or not the	e citatio	DATE CONS		line through the	citation if not	in
			clude a copy of this form				anough the	vitation if not	

PTO/SB/ 08 (2-92) pa- 841304

Form PTO-1449			Docket Number 252312005706 Application Num		umber 09/753,3	550			
OINFORMATION DISCLOSURE CITATION			Applicant						
N AN APPLICATION			Stephen M. COUTTS et al.						
FEB 1.3 2004 H(Use several sheets if necessary)			Filing Date December 29), 2000	Group Art Uni	t 1644			
<u> </u>					Mailing Date February 5	, 2004			
RADE	C.			· · · · ·		-			
	53.	06/17/1999	WO 99/29338	WI	PO	<u> </u>			
	54.	07/15/1999	WO 99/34833	WI	PO				
	55.	09/23/1999	WO 99/47494	WI	PO			Abstract	
	56.	06/15/2000	WO 00/33887	WI	PO				
	57.	06/15/2000	WO 00/34231	WI	PO				
	58.	06/15/2000	WO 00/34296	WI	РО	<u> </u>		ļ	
			OTHE	R D	OCUMENTS	(includ	ing author, title, D	ate, Pertinent Pa	nges, Etc.)
Examiner Initials	Ref. No.	Title					~		
	59.	Ashton, P. R	. et al. (1996). "Amir	10 Ac	cid Derivatives of β-	Cyclodextr	in," J. Org. C	hem. 61:90.	3-908.
	60. Bordunov, A. V. et al. (1995). "Synthesis of New Pyridinoazacrown Ethers Containing Aromatic and Heteroaromatic Proton Ionizable Substituents," J. Org. Chem. 60: 6097-6102.								
	61.	Borel, H. et al. (1984). "Conjugation of DNA Fragments to Protein Carriers by Glutaraldehyde: Immunogenicity of Oligonucleotide-Hemocyanin Conjugates," <i>Journal of Immunological Methods</i> 67:289-302.							
	62.	Brask, J. and Jensen, K.J. (2001). "Carboproteins: A 4-α-Helix Bundle Protein Model Assembled on a D-Galactopyranoside Template," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:697-700.							
	63.	Choi, J.S. et al. (1999). "Poly(ethylene glycol)-block-poly(L-lysine) Dendrimer: Novel Linear Polymer/Dendrimer Block Copolymer Forming a Spherical Water-Soluble Polyionic Complex with DNA," <i>Bioconjug. Chem.</i> 10(1):62-65.							
	64.	Choi, J.S. et al. (2000). "Synthesis of a Barbell-like Triblock Copolymer, Poly(L-lysine) Dendrimer-block-Poly(ethylene glycol)-block-Poly(L-lysine) Dendrimer, and Its Self-Assembly with Plasmid DNA," J. Am. Chem. Soc. 122(3):474-480.							
	65.	Clark, A.J. et al. (2001). "A Nonisocyanate Route to Monodisperse Branched Polyurethanes," J. Org. Chem. 66:8687-8689.							
	66. Conrad, M.J. and Coutts, S. (1991). "Conjugates of Stable Polymer and Polynucleotide - Tolerogens for Human Systemic Lupus Erythematosus," Derwents Database record for European Patent No. EP 0 438 259, July 1991.								
	67.	Contreras, M. A. et al. (1983). "Iodine Monochloride (ICI) Iodination Techniques" Chapter 22 In Methods in Enzymology Academic Press, Inc.: New York, New York 92:277-292.							
	68.	Duncan, R. (1985). "Biological Effects of Soluble Synthetic Polymers as Drug Carriers," CRC Critical Reviews in Therapeutic Drug Carrier Systems. 1(4): 281-310.							
	69.	Duncan, R. and Spreafico, F. (1994). "Polymer Conjugates: Pharmacokinetic Considerations for Design and Development," <i>Clin. Pharmacokinetic</i> 27(4):290-306.							
EXAMI	NER:				DATE CONSI	DERED:			
			dered, whether or not the				line through the	citation if not	in

PTO/SB/ 08 (2-92) pa- 841304

Form PTO-1449			Docket Number 252312005706	Application Number 09/753,350			
N AN APPLICATION		ON DISCLOSURE CITATION	Applicant				
		AN APPLICATION	Stephen M. COUTTS et al.				
/ _ 200		lse several sheets if necessary)	Filing Date December 29, 2000	Group Art Unit 1644			
FEB 1 3 200			Mailing Date February 5, 2004				
E.	3 9						
FEB 13 A	7 . ·	Eisenbach, C. D. and Heinemann, T. (Copolymer Elastomers with a Polyethe Macromolecules 28(7):2133-2139.					
7	71.	Eisenbach, C. D. and Heinemann, T. (Chain-Folding or Bifurcated Side Chain					
7	72.	Fischer, M. and Vögtle, F. (1999). "Dangew. Chem. Int. Ed. 38:885-905.	endrimers: From Design to App	olication - A Progress Report,"			
7	73.	Gadelle, A. and Defaye, J. (1991). "Se Cyclomaltooligosaccharides and a Syn Angew. Chem. Int. Ed. Engl. 30:78-80.	nthesis of Per-3,6-anhydro Cyclo				
7	74.	Gennaro, A. R., ed. (1995). Remington Publishing Co., Easton: Pennsylvania,					
7	75. Gitsov, I. et al. (1992). "Novel Polyether Copolymers Consisting of Linear and Dendritic Blocks," <i>Angew. Chem. Int. Ed. Engl.</i> 31(9): 1200-1202.						
7	76.	Huang, S-Y. et al. (1998). "A Polyethylene Glycol Copolymer for Carrying and Releasing Multiple Copies of Cysteine-Containing Peptides," <i>Bioconjug. Chem.</i> 9(5): 612-617.					
7	77.	Iverson, G. M. et al. (1998). "A Chemically Defined, Toleragen-Based Approach for Targeting Anti- β_2 -Glycoprotein I Antibodies," <i>Lupus</i> 7(Supp. 2):S166-S169.					
7	78.	Iverson, G. M. et al. (1998). "Anti-β2 Glycoprotein I (β2GPI) Autoantibodies Recognize an Epitope on the First Domain of β2GPI," <i>Proc. Nat. Acad. Sci.</i> 95:15542-15546.					
7	79.	King, T.P. et al. (1993). "Structure-Immunogenicity Relationship of Melittin and Its N-Terminal Truncated Analogs," <i>Biochemistry</i> 32(13):3506-3510.					
8	30.	Kono, K. et al. (1999). "Design of Den Residues," <i>Bioconjug. Chem.</i> 10(6):11		ing Folate or Methotrexate			
8	31.	Kuo, J. et al. (1991). "Chemical Modif Chem. 2(4):232-241.	ication of Hyaluronic Acid by C	Carbodiimides," Biocongjugate			
. 8	32.	Lee, L. S. et al. (1999). "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene Glycol: A Comparison of Conjugation Chemistries and Compounds," <i>Bioconjug Chem</i> 10(6):973-981.					
8	33.	Leonetti, J.P. (1988). "Antiviral Activity of Conjugates Between Poly(l-lysine) and Synthetic Oligodeoxyribonucleotides," <i>Gene</i> 72:323-332.					
8	34.	Lu, C. X. et al. (1988). "Nucleic Acid Base Grafted Imino Polyurethane," J. Polymer Sci./ Part A: Polymer Chem. 26(6):1659-1669.					
8	35.	McMurry, T.J. et al. (1992). "Convenience Bioconjugate Chem. 3(2):108-117.	ent Sythesis of Bifunctional Tetr	raaza Macrocycles,"			
			DAME CONGINEDED				
EXAMINE	R:		DATE CONSIDERED:				
		al if citation considered, whether or not the citation considered. Include a copy of this form with no		ine through the citation if not in			

Docket Number 252312005706 Application Number 09/753,350 Form PTO-1449 TOTOR MATION DISCLOSURE CITATION Applicant Stephen M. COUTTS et al. MAN APPLICATION several sheets if necessary) Filing Date December 29, 2000 Group Art Unit 1644 FEB 1 3 2004 (C Mailing Date February 5, 2004 TRADEPAS Mitchell, J. P.et al. (1999). "A Direct Method for the Formation of Peptide and Carbohydrate Dendrimers," Bioorganic & Medicinal Chemistry Letters 9:2785-2788. 87. Pechar, M. et al. (2000). "Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin," Bioconjug. Chem. 11(2):131-139. 88. Savva, M. et al. (1999). "A Genetically Modified Recombinant Tumor Necrosis Factor-α Conjugated to the Distal Terminals of Liposomal Surface Grafted Polyethyleneglycol Chains," Int. J. Pharm. 184: 45-51. 89. Talarico, T. L. et al. (2000). "Chemical Characterization of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate," Biochim. Biophys. Acta 1476:53-65. 90. Taylor, R.T. and Puapaiboon, U. (1998). "Polyurethane Dendrimers via Curtius Reaction," Tetrahedron Lett. 39:8005-8008. Vercruysse, K.P. et al. (1997). "Synthesis and in Vitro Degradation of New Polyvalent Hydrazide 91. Cross-Linked Hydrogels of Hyaluronic Acid," Bioconjugate Chem. 8:686-694. Veronese, F.M. and Morpurgo, M. (1999). "Bioconjugation in Pharmaceutical Chemistry," Il 92. Farmaco 54:497-516. 93. Webb, M.S. et al. (1998). "Comparison of Different Hydrophobic Anchors Conjugated to Poly(ethylene glycol): Effects on the Pharmacokinetics of Liposomal Vincristine," Biochim. Biophys. Acta 1372:272-282.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 841304 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE